84 related articles for article (PubMed ID: 23400739)
1. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.
Wang X; Kay A; Anak O; Angevin E; Escudier B; Zhou W; Feng Y; Dugan M; Schran H
J Clin Pharmacol; 2013 Jan; 53(1):14-20. PubMed ID: 23400739
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
3. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
4. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
[TBL] [Abstract][Full Text] [Related]
5. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.
Porta C; Giglione P; Liguigli W; Paglino C
Future Oncol; 2015; 11(1):39-50. PubMed ID: 25572783
[TBL] [Abstract][Full Text] [Related]
6. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
[TBL] [Abstract][Full Text] [Related]
10. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
Hahn NM; Bivalacqua TJ; Ross AE; Netto GJ; Baras A; Park JC; Chapman C; Masterson TA; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Jones DR; McElyea K; Sandusky GE; Breen T; Liu Z; Albany C; Moore ML; Loman RL; Reed A; Turner SA; De Abreu FB; Gallagher T; Tsongalis GJ; Plimack ER; Greenberg RE; Geynisman DM
Clin Cancer Res; 2017 Jun; 23(12):3003-3011. PubMed ID: 27932416
[No Abstract] [Full Text] [Related]
12. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
Lee SH; Lopes de Menezes D; Vora J; Harris A; Ye H; Nordahl L; Garrett E; Samara E; Aukerman SL; Gelb AB; Heise C
Clin Cancer Res; 2005 May; 11(10):3633-41. PubMed ID: 15897558
[TBL] [Abstract][Full Text] [Related]
13. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
Yoo C; Ryu MH; Na YS; Ryoo BY; Park SR; Kang YK
Ann Oncol; 2014 Nov; 25(11):2272-2277. PubMed ID: 25149706
[TBL] [Abstract][Full Text] [Related]
14. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D
Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D; Barker D; Sharma R; Brunetto AT; Yap TA; Taegtmeyer AB; Barriuso J; Medani H; Degenhardt YY; Allred AJ; Smith DA; Murray SC; Lampkin TA; Dar MM; Wilson R; de Bono JS; Blagden SP
Clin Cancer Res; 2011 May; 17(10):3420-30. PubMed ID: 21459796
[TBL] [Abstract][Full Text] [Related]
16. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
17. Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.
Quintela-Fandino M; Bueno MJ; Lombardia L; Gil M; Gonzalez-Martin A; Marquez R; Bratos R; Guerra J; Tan E; Lopez A; Colomer R; Salazar R
Mol Oncol; 2014 Dec; 8(8):1719-28. PubMed ID: 25103625
[TBL] [Abstract][Full Text] [Related]
18. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Clemens A; Haertter S; Friedman J; Brueckmann M; Stangier J; van Ryn J; Lehr T
Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
[TBL] [Abstract][Full Text] [Related]
19. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
